Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis

Davide Melisi, Satoshi Ishiyama, Guido M. Sclabas, Jason B. Fleming, Qianghua Xia, Giampaolo Tortora, James L. Abbruzzese and Paul J. Chiao
Davide Melisi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoshi Ishiyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guido M. Sclabas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason B. Fleming
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qianghua Xia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giampaolo Tortora
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James L. Abbruzzese
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul J. Chiao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-07-0337 Published April 2008
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: April 2008 to January 2021

AbstractFull-text HTMLPDF
Total439461793886

Cited By

Article Information

Volume 7, Issue 4, pp. 829-840

DOI 
https://doi.org/10.1158/1535-7163.MCT-07-0337
PubMed 
18413796

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • February 28, 2008
  • May 14, 2007
  • January 8, 2008
  • Published first April 15, 2008.

Copyright & Usage 
American Association for Cancer Research

Author Information

  1. Davide Melisi1,
  2. Satoshi Ishiyama2,
  3. Guido M. Sclabas2,
  4. Jason B. Fleming2,
  5. Qianghua Xia2,
  6. Giampaolo Tortora4,
  7. James L. Abbruzzese1 and
  8. Paul J. Chiao23
  1. 1Department of Gastrointestinal Medical Oncology and 2Surgical Oncology and Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center; 3Program of Cancer Biology, Graduate School of Biomedical Sciences, University of Texas-Houston Health Science Center, Houston, Texas; and 4Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università di Napoli “Federico II,” Naples, Italy
  1. Requests for reprints: Paul J. Chiao, Department of Surgical Oncology, Unit 107, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-794-1030; Fax: 713-794-4830. E-mail: pjchiao{at}mdanderson.org
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 7 (4)
April 2008
Volume 7, Issue 4
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
Davide Melisi, Satoshi Ishiyama, Guido M. Sclabas, Jason B. Fleming, Qianghua Xia, Giampaolo Tortora, James L. Abbruzzese and Paul J. Chiao
Mol Cancer Ther April 1 2008 (7) (4) 829-840; DOI: 10.1158/1535-7163.MCT-07-0337

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
Davide Melisi, Satoshi Ishiyama, Guido M. Sclabas, Jason B. Fleming, Qianghua Xia, Giampaolo Tortora, James L. Abbruzzese and Paul J. Chiao
Mol Cancer Ther April 1 2008 (7) (4) 829-840; DOI: 10.1158/1535-7163.MCT-07-0337
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells
  • Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
  • Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement